Trovagene Inc (TROV) 5.20 $TROV
Clinical Study Results Featuring Trovagene's Precision Cancer Monitoring Platform to be Presented at the AACR Annual Meeting 2016
PR Newswire - Thu Mar 24, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that clinical results for the Company's Precision Cancer Monitoring® platform will be presented by Dr. Takeo Fujii of the University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2016.
TROV: 5.20 (-0.12)
Why Healthcare Investors Should Forget about Drug Companies and Focus on Medical Device Companies
ACCESSWIRE - Mon Mar 21, 12:25PM CDT
WINDSOR, ON / ACCESSWIRE / March 21, 2016 / The Wealthy Biotech Trader (or "WBT"
, is an investment newsletter focused on presenting everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks, which are making news and subsequent market moves. WBT would like to shed some light on the bubble among the big pharma companies and draw attention to smaller, yet highly innovative companies making their presence felt in the medical device sector. We will focus on our highlighted company, Endonovo Therapeutics, Inc. (OTCQB: ENDV), which we will compare to and contrast to a few others in the space.
CSII: 9.52 (-0.08), TROV: 5.20 (-0.12)
TrovaGene (TROV) Falls on Wider-than-Expected Q4 Loss
Zacks Equity Research - Zacks Investment Research - Fri Mar 11, 8:20AM CST
TrovaGene Inc (TROV) reported adjusted loss of 27 cents per share in the fourth quarter of 2015, wider than the year-ago loss of 25 cents.
ABMD: 90.60 (-0.94), TROV: 5.20 (-0.12), LMNX: 18.78 (unch), CRY: 10.40 (-0.07)
/C O R R E C T I O N -- Trovagene, Inc./
PR Newswire - Thu Mar 10, 10:40PM CST
In the news release, Trovagene Announces Fourth Quarter and Year End 2015 Financial Results, issued 10-Mar-2016 by Trovagene, Inc. over PR Newswire, we are advised by the company that in the Condensed Consolidated Statements of Operations table, in the Diagnostic service revenue and Other revenue line items, under the Three Months Ended December 31, 2015 column, the numbers should read "3" and "24", respectively, rather than "24" and "3", as originally issued inadvertently. The complete, corrected release follows:
TROV: 5.20 (-0.12)
Trovagene reports 4Q loss
Automated Insights - Thu Mar 10, 5:17PM CST
SAN DIEGO (AP) _ Trovagene Inc. (TROV) on Thursday reported a loss of $7.4 million in its fourth quarter.
TROV: 5.20 (-0.12)
Trovagene Announces Fourth Quarter and Year End 2015 Financial Results
PR Newswire - Thu Mar 10, 3:13PM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and year ended December 31, 2015.
TROV: 5.20 (-0.12)
Presentation at the Molecular Medicine Tri-Conference to Highlight Clinical Performance of Trovagene's Precision Cancer Monitoring Platform
PR Newswire - Tue Mar 08, 7:15AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will be presenting at the Molecular Medicine Tri-Conference 2016, highlighting clinical performance of the Company's Precision Cancer Monitoring® (PCM) technology and how high sensitivity and the ability to quantitate mutational load translates into clinical applications for treating late-stage cancer patients. Vlada Melnikova, M.D., Ph.D., will deliver the presentation on March 10, 2016 at 12:15 p.m. (PST) in San Francisco, CA. The presentation, entitled Pharmacodynamic Assessment of Drug Response by Monitoring Mutational Load in Urinary Circulating Tumor DNA, will feature data from clinical studies in both lung and pancreatic cancer.
TROV: 5.20 (-0.12)
What's in Store for TrovaGene (TROV) in Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Mar 07, 10:00AM CST
TrovaGene Inc. (TROV) is scheduled to report fourth-quarter 2015 earnings results on Mar 10.
TROV: 5.20 (-0.12), KMDA: 3.89 (+0.08), AMGN: 149.24 (+0.48), MDXG: 8.25 (+0.03)
Franklin Square Provides Financing for New Mountain Capital's Acquisitions and Combination of Trover Solutions and Equian
PR Newswire - Thu Mar 03, 7:00AM CST
Franklin Square Capital Partners, the largest manager of business development companies (BDCs), announced the origination of a $260 million unitranche term loan to support the acquisition and combination of Trover Solutions, Inc. and Equian LLC by New Mountain Capital, LLC (New Mountain), a New York-based alternative investments firm that manages approximately $15 billion of private equity, public equity and credit assets.
TROV: 5.20 (-0.12), FSIC: 8.93 (-0.08)
TrovaGene (TROV) Inks Deal with Multiplan; Shares Rally
Zacks Equity Research - Zacks Investment Research - Wed Mar 02, 12:10PM CST
Shares of molecular diagnostic company TrovaGene (TROV) jumped 11.8% (61 cents) to close at $5.76 on Mar 1, following the announcement of a new strategic agreement with Multiplan.
ABMD: 90.60 (-0.94), TROV: 5.20 (-0.12), LMNX: 18.78 (unch), CRY: 10.40 (-0.07)
Here’s Why TrovaGene (TROV) Stock is Soaring Today
at The Street - Mon Feb 01, 12:14PM CST
TrovaGene (TROV) stock is spiking on Monday afternoon as the company enters an agreement with FedMed for access to cancer monitoring tests and services.
TROV: 5.20 (-0.12)
Why TrovaGene (TROV) Stock is Surging Today
Madeleine Johnson - Zacks Investment Research - Mon Feb 01, 11:58AM CST
On Monday, shares of TrovaGene Inc (TROV) are surging almost 20% after the company announced that they reached an agreement with healthcare company FedMed Inc.
CIG: 2.15 (+0.05), TROV: 5.20 (-0.12), AET: 112.41 (+0.66), HUM: 184.07 (+0.48)
Trovagene Enters into Agreement with FedMed, Inc. and Significantly Expands Patient Access to Its Precision Cancer Monitoring Platform
PR Newswire Europe - Mon Feb 01, 2:01AM CST
FedMed brings in-network health plan access to an additional 40 million covered lives
TROV: 5.20 (-0.12)
Why Is Trovagene Inc. (TROV) Stock Soaring Today?
Ryan McQueeney - Zacks Investment Research - Thu Jan 21, 3:27PM CST
Shares of molecular diagnostics company Trovagene (TROV) are soaring today following news that the company has reached an agreement with America's Choice Provider Network (ACPN). Trovagene has gained over $2 or 60%% during regular trading hours Thursday.
TROV: 5.20 (-0.12)
Trovagene (TROV) Stock Soars on America's Choice Provider Network Partnership
at The Street - Thu Jan 21, 1:28PM CST
Trovagene (TROV) stock is climbing on heavy trading volume on Thursday after the company announced a partnership with America's Choice Provider Network.
TROV: 5.20 (-0.12)
4 Nasdaq Stocks That Are Trading Higher Today
ACCESSWIRE - Thu Jan 21, 10:35AM CST
NEW YORK, NY / ACCESSWIRE / January 21, 2016 / The Stock Expert is issuing a report on four stocks to watch. TROV, AGEN, PFSW and ENPH have been attracting the attention of major investors today. Continue reading to find out why. To get more reports on current stocks subscribe to our newsletter at TheStockExpert.com.
AGEN: 3.91 (+0.08), ENPH: 2.21 (-0.05), TROV: 5.20 (-0.12), PFSW: 12.25 (+0.13)
Trovagene Announces Agreement with America's Choice Provider Network to Offer Patients Access to its ctDNA Precision Cancer Monitoring Platform
PR Newswire - Thu Jan 21, 7:15AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it has entered into an agreement with America's Choice Provider Network (ACPN®) establishing health insurance access to its entire suite of circulating tumor (ct)DNA Precision Cancer Monitoringâ" (PCM) tests and services. Under the terms of the agreement, Trovagene is established as a preferred provider, and its PCM testing services will be covered by over 1,700 payers in North America.
TROV: 5.20 (-0.12)
Clinical Study Results Featuring Trovagene's Precision Cancer Monitoring Platform to be Presented at the AACR Annual Meeting 2016
PR Newswire - Thu Mar 24, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that clinical results for the Company's Precision Cancer Monitoring® platform will be presented by Dr. Takeo Fujii of the University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2016.
TROV: 5.20 (-0.12)
Why Healthcare Investors Should Forget about Drug Companies and Focus on Medical Device Companies
ACCESSWIRE - Mon Mar 21, 12:25PM CDT
WINDSOR, ON / ACCESSWIRE / March 21, 2016 / The Wealthy Biotech Trader (or "WBT"
, is an investment newsletter focused on presenting everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks, which are making news and subsequent market moves. WBT would like to shed some light on the bubble among the big pharma companies and draw attention to smaller, yet highly innovative companies making their presence felt in the medical device sector. We will focus on our highlighted company, Endonovo Therapeutics, Inc. (OTCQB: ENDV), which we will compare to and contrast to a few others in the space. CSII: 9.52 (-0.08), TROV: 5.20 (-0.12)
TrovaGene (TROV) Falls on Wider-than-Expected Q4 Loss
Zacks Equity Research - Zacks Investment Research - Fri Mar 11, 8:20AM CST
TrovaGene Inc (TROV) reported adjusted loss of 27 cents per share in the fourth quarter of 2015, wider than the year-ago loss of 25 cents.
ABMD: 90.60 (-0.94), TROV: 5.20 (-0.12), LMNX: 18.78 (unch), CRY: 10.40 (-0.07)
/C O R R E C T I O N -- Trovagene, Inc./
PR Newswire - Thu Mar 10, 10:40PM CST
In the news release, Trovagene Announces Fourth Quarter and Year End 2015 Financial Results, issued 10-Mar-2016 by Trovagene, Inc. over PR Newswire, we are advised by the company that in the Condensed Consolidated Statements of Operations table, in the Diagnostic service revenue and Other revenue line items, under the Three Months Ended December 31, 2015 column, the numbers should read "3" and "24", respectively, rather than "24" and "3", as originally issued inadvertently. The complete, corrected release follows:
TROV: 5.20 (-0.12)
Trovagene reports 4Q loss
Automated Insights - Thu Mar 10, 5:17PM CST
SAN DIEGO (AP) _ Trovagene Inc. (TROV) on Thursday reported a loss of $7.4 million in its fourth quarter.
TROV: 5.20 (-0.12)
Trovagene Announces Fourth Quarter and Year End 2015 Financial Results
PR Newswire - Thu Mar 10, 3:13PM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and year ended December 31, 2015.
TROV: 5.20 (-0.12)
Presentation at the Molecular Medicine Tri-Conference to Highlight Clinical Performance of Trovagene's Precision Cancer Monitoring Platform
PR Newswire - Tue Mar 08, 7:15AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will be presenting at the Molecular Medicine Tri-Conference 2016, highlighting clinical performance of the Company's Precision Cancer Monitoring® (PCM) technology and how high sensitivity and the ability to quantitate mutational load translates into clinical applications for treating late-stage cancer patients. Vlada Melnikova, M.D., Ph.D., will deliver the presentation on March 10, 2016 at 12:15 p.m. (PST) in San Francisco, CA. The presentation, entitled Pharmacodynamic Assessment of Drug Response by Monitoring Mutational Load in Urinary Circulating Tumor DNA, will feature data from clinical studies in both lung and pancreatic cancer.
TROV: 5.20 (-0.12)
What's in Store for TrovaGene (TROV) in Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Mar 07, 10:00AM CST
TrovaGene Inc. (TROV) is scheduled to report fourth-quarter 2015 earnings results on Mar 10.
TROV: 5.20 (-0.12), KMDA: 3.89 (+0.08), AMGN: 149.24 (+0.48), MDXG: 8.25 (+0.03)
Franklin Square Provides Financing for New Mountain Capital's Acquisitions and Combination of Trover Solutions and Equian
PR Newswire - Thu Mar 03, 7:00AM CST
Franklin Square Capital Partners, the largest manager of business development companies (BDCs), announced the origination of a $260 million unitranche term loan to support the acquisition and combination of Trover Solutions, Inc. and Equian LLC by New Mountain Capital, LLC (New Mountain), a New York-based alternative investments firm that manages approximately $15 billion of private equity, public equity and credit assets.
TROV: 5.20 (-0.12), FSIC: 8.93 (-0.08)
TrovaGene (TROV) Inks Deal with Multiplan; Shares Rally
Zacks Equity Research - Zacks Investment Research - Wed Mar 02, 12:10PM CST
Shares of molecular diagnostic company TrovaGene (TROV) jumped 11.8% (61 cents) to close at $5.76 on Mar 1, following the announcement of a new strategic agreement with Multiplan.
ABMD: 90.60 (-0.94), TROV: 5.20 (-0.12), LMNX: 18.78 (unch), CRY: 10.40 (-0.07)
Here’s Why TrovaGene (TROV) Stock is Soaring Today
at The Street - Mon Feb 01, 12:14PM CST
TrovaGene (TROV) stock is spiking on Monday afternoon as the company enters an agreement with FedMed for access to cancer monitoring tests and services.
TROV: 5.20 (-0.12)
Why TrovaGene (TROV) Stock is Surging Today
Madeleine Johnson - Zacks Investment Research - Mon Feb 01, 11:58AM CST
On Monday, shares of TrovaGene Inc (TROV) are surging almost 20% after the company announced that they reached an agreement with healthcare company FedMed Inc.
CIG: 2.15 (+0.05), TROV: 5.20 (-0.12), AET: 112.41 (+0.66), HUM: 184.07 (+0.48)
Trovagene Enters into Agreement with FedMed, Inc. and Significantly Expands Patient Access to Its Precision Cancer Monitoring Platform
PR Newswire Europe - Mon Feb 01, 2:01AM CST
FedMed brings in-network health plan access to an additional 40 million covered lives
TROV: 5.20 (-0.12)
Why Is Trovagene Inc. (TROV) Stock Soaring Today?
Ryan McQueeney - Zacks Investment Research - Thu Jan 21, 3:27PM CST
Shares of molecular diagnostics company Trovagene (TROV) are soaring today following news that the company has reached an agreement with America's Choice Provider Network (ACPN). Trovagene has gained over $2 or 60%% during regular trading hours Thursday.
TROV: 5.20 (-0.12)
Trovagene (TROV) Stock Soars on America's Choice Provider Network Partnership
at The Street - Thu Jan 21, 1:28PM CST
Trovagene (TROV) stock is climbing on heavy trading volume on Thursday after the company announced a partnership with America's Choice Provider Network.
TROV: 5.20 (-0.12)
4 Nasdaq Stocks That Are Trading Higher Today
ACCESSWIRE - Thu Jan 21, 10:35AM CST
NEW YORK, NY / ACCESSWIRE / January 21, 2016 / The Stock Expert is issuing a report on four stocks to watch. TROV, AGEN, PFSW and ENPH have been attracting the attention of major investors today. Continue reading to find out why. To get more reports on current stocks subscribe to our newsletter at TheStockExpert.com.
AGEN: 3.91 (+0.08), ENPH: 2.21 (-0.05), TROV: 5.20 (-0.12), PFSW: 12.25 (+0.13)
Trovagene Announces Agreement with America's Choice Provider Network to Offer Patients Access to its ctDNA Precision Cancer Monitoring Platform
PR Newswire - Thu Jan 21, 7:15AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it has entered into an agreement with America's Choice Provider Network (ACPN®) establishing health insurance access to its entire suite of circulating tumor (ct)DNA Precision Cancer Monitoringâ" (PCM) tests and services. Under the terms of the agreement, Trovagene is established as a preferred provider, and its PCM testing services will be covered by over 1,700 payers in North America.
TROV: 5.20 (-0.12)
